Dr. Bishoy Faltas (2015 Young Investigator Award) of Weill Cornell Medicine studies the changes in bladder cancer that lead to treatment resistance as well as develops strategies to reverse or prevent that resistance.

Dr. Supriya Mohile (2004 Young Investigator Award) of the University of Rochester was one of the first people to complete training in geriatric oncology; she oversees two large clinical trials that aim to improve outcomes for older patients with cancer.

Dr. Waterhouse (1992 Young Investigator Award, (2) Clinical Trial Participation Awards) of Oncology Hematology Care knows firsthand how impactful grants like the YIA can be to researchers just beginning their quests to conquer cancer.

Dr. William (2009 Young Investigator Award, 2012 Career Development Award) of MD Anderson Cancer Center investigates new therapies for people with cancer as well as ways to prevent cancer in people with pre-malignant lesions.

Dr. Johnson (2014 Young Investigator Award, 2015 Career Development Award) of Vanderbilt University explores why only some people with melanoma respond to immunotherapy and investigates new treatment options.

Dr. Brastianos (2012 Young Investigator Award) of Massachusetts General Hospital Cancer Center and Harvard Medical School and investigates why and how cancer travels to the brain from other places, which could lead to better treatments for patients.

Dr. Bedrosian (2010 Advanced Clinical Research Award in Breast Cancer) and her team at The University of Texas MD Anderson Cancer Center discovered a number of tissue-based biomarkers associated with increased breast cancer risk.

Dr. Grisham (2014 Career Development Award) of Memorial Sloan Kettering Cancer Center and her team are examining the effects of enzalutamide, a drug approved to treat men with advanced prostate cancer, on androgen receptor positive (AR+) ovarian cancer.

Dr. Jain (2013 Young Investigator Award) of Beth Israel Deaconess Medical Center is pursuing a new treatment for cutaneous t-cell lymphoma (CTCL), a rare type of cancer that can affect the skin, blood, lymph nodes, and more.

Dr. Allen-Rhoades (2013 Young Investigator Award) of Baylor College of Medicine/Texas Children's Hospital investigates a rapid blood test as an easier, safer and more accurate screening method to detect the presence of osteosarcoma. This rare but devastating disease is the most common type of bone cancer in children.

Dr. Mya Thida (International Innovation Grant), head of the obstetrics and gynecology department at the University of Medicine 1, Yangon, created a breakthrough “single visit” model for cervical cancer detection to serve rural villages, using visual screening and immediate cryotherapy provided in mobile units.

Dr. Ko (2012 Young Investigator Award) of University of Pennsylvania investigates a new method for treating endometrial hyperplasia, an unusual development of the lining of the uterus that is a precursor to endometrial cancer.

The link between obesity and breast cancer has long been established, but Dr. Neil Iyengar, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center and recipient of a 2013 Conquer Cancer Foundation of ASCO Young Investigator Award, was not satisfied that we have the full story.

Across the cancer community in the United States disparities in the access to quality cancer care is an area of deep concern. These disparities are differences that exist among specific population groups in the United States in cancer diagnosis, treatment, and long-term outcomes.

Nearly all Conquer Cancer Foundation researchers are not only at work unlocking new discoveries in the lab – most are also taking care of patients on a daily basis, getting a chance to see the impact of their work in action.

Jacquelyne Gaddy, a medical student at Loyola University Chicago, was awarded an MSR (Medical Student Rotation for Underrepresented Populations) in 2012 and helped solidify her interest in and passion for oncology.

Dr. Sanjay Goel of the Albert Einstein College of Medicine works to help patients who, because of mutation in the KRAS gene of their colorectal cancer, are ineligible to receive certain targeted therapies.

Cancer accounts for more deaths in low- and middle-income countries than tuberculosis, malaria, and AIDS combined, with more than 2/3 of cancer deaths worldwide occurring in those countries. That’s why the Conquer Cancer Foundation supports talented oncologists and researchers like Dr. Dauren Adilbay of the Astana Cancer Center in Kazakhstan.

Dr. Wright, recipient of a 2009 Young Investigator Award and a 2010 Career Development Award from the Conquer Cancer Foundation, wondered if there might be key genetic differences between the two types of cervical cancer that could respond to more tailored treatment.

Dr. Leslie Doros of Children’s National Medical Center has a passion for helping kids with rare cancers and received a grant to start a clinic at the National Institute of Health for children with pleuropulmonary blastoma (PPB), a rare pediatric lung cancer.

Dr. Oxnard’s current project originated as an idea sparked by the research supported by his Conquer Cancer Foundation Young Investigator Award in 2010, which explored resistance and sensitivity to a drug called erlotinib that is used to treat lung cancer.

For Dr. Jane Churpek, Assistant Professor at the University of Chicago, her 2011 Conquer Cancer Foundation of ASCO Young Investigator Award was a critical first step in making her research career possible.

Abby Rosenberg, MD, MS, an acting instructor at Seattle Children’s Hospital, noticed that some families were more able than others to absorb the seismic life changes brought on by a cancer diagnosis, and that those families, in turn, were able to provide the best possible environment for a child with cancer.

Conquer Cancer Foundation

The Conquer Cancer Foundation® is registered in Virginia as a nonprofit corporation. The Conquer Cancer Foundation is a public charity exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code and the organization’s Federal Identification Number (EIN) is 31-1667995.

Conquer Cancer Foundation

The Conquer Cancer Foundation® is registered in Virginia as a nonprofit corporation. The Conquer Cancer Foundation is a public charity exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code and the organization’s Federal Identification Number (EIN) is 31-1667995.